Colchicine reduces the risk of COVID-19-related complications

January 23, 2021

Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Read more

Second year of the Montreal Heart Institute’s Diabetes Prevention Clinic sponsored by Sun Life

January 15, 2021

Supporting people with type 2 diabetes throughout the pandemic

Read more

New data supports development of colchicine for the prevention of acute respiratory distress syndrome

December 7, 2020

This syndrome can develop in patients with COVID-19 if the virus enters the respiratory tract and damages the lungs

The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models1. The article reporting these results was published yesterday by the Public Library of Science ONE (PLOS ONE) 1.

Read more